Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX1206 in T2DM Patients with NAFLD
NCT06694935Phase 1Recruiting
- Sponsor
- 1Globe Health Institute
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QX1206 in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), sponsored by 1Globe Health Institute. Primary endpoint: Recommended Phase 2 Dose at 12 weeks. Started Jan 2025; status: recruiting.
02
Drugs
QX1206
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06694935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694935.